<DOC>
	<DOCNO>NCT00548470</DOCNO>
	<brief_summary>This open label pre-post study effect clinical treatment varenicline 1 ) decrease smoke schizophrenic patient , 2 ) improving select cognitive measure schizophrenic patient , 3 ) effect nicotinic bind leukocyte DNMT1 mRNA lymphocyte . Patients assess subjective objective measure smoke , select cognitive measure , special chemical measure , baseline test 8 week treatment varenicline ( 1-3 mg/day ) .</brief_summary>
	<brief_title>Varenicline Effects In Schizophrenic Smokers</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Varenicline</mesh_term>
	<criteria>Clinical Diagnosis Schizophrenia Schizoaffective Psychosis Recent History Cigarette smoking Ages 1865</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>varenicline</keyword>
	<keyword>cognition</keyword>
	<keyword>cigarette smoking</keyword>
</DOC>